Deepika Sharma
Deepika Sharma has a total of 11 co-authors. Here are the top co-authors by number of shared publications:
- Gopal Singh Bisht
Department of Biotechnology and Bioinformatics, Jaypee University of Information Technology, Waknaghat, India
4 shared publications Manu Sharma
National Forensic Sciences University Delhi Campus, New Delhi, India
2 shared publications- Abhishek Chaudhary
Department of Biotechnology and Bioinformatics, Jaypee University of Information Technology, Waknaghat, India
1 shared publication - Ashish Jain
Secretary, Indian Society of Periodontology, Professor and Head, Department of Periodontology, Dr. Harvansh Singh Judge Institute of Dental Sciences and Hospital, Panjab University, Chandigarh, India
1 shared publication - Bhavna Kumar
Faculty of Pharmacy, DIT University, Dehradun, Uttarakhand, India
1 shared publication - Samir Bhargava
School of Pharmaceutical & Population Health Informatics, DIT University, Dehradun, India
1 shared publication
Latest Publications
- 1 February 2023
- Published by Bentham Science Publishers Ltd. in Current Cancer Therapy Reviews
- Vol. 19 (1) , 2-12
Recent Updates on Folate Targeted Drug Delivery Systems in Cancer: A Mini Review
Targeted drug delivery systems that selectively deliver anticancer drugs to tumour cells have always been a field of interest to reduce side effects associated with chemotherapy in cancer patients. Cancer cells require nutrients for their multiplication; folic acid is one such nutrient. Expression of folate receptors is negligible in normal cells, whereas they are overexpressed in a variety of cancer cells. A number of studies have shown that selective targeting of folate receptors in cancer is a beneficial approach, as folate targeted anticancer conjugates are selective towards cancer cells, thereby sparing non-cancerous cells. In this review, we have discussed folate receptor, folic acid as a cancer targeting moiety, different folate targeted anticancer drug conjugates, and different folate conjugated nanodelivery systems. This summarized information may turn out to be valuable for researchers to design novel folate targeted anticancer drug delivery systems having the potential to reduce the drawbacks associated with conventional cancer therapeutics.
- 1 February 2023
- Published by Bentham Science Publishers Ltd. in Current Cancer Therapy Reviews
- Vol. 19 (1) , 2-12
Recent Updates on Folate Targeted Drug Delivery Systems in Cancer: A Mini Review
Targeted drug delivery systems that selectively deliver anticancer drugs to tumour cells have always been a field of interest to reduce side effects associated with chemotherapy in cancer patients. Cancer cells require nutrients for their multiplication; folic acid is one such nutrient. Expression of folate receptors is negligible in normal cells, whereas they are overexpressed in a variety of cancer cells. A number of studies have shown that selective targeting of folate receptors in cancer is a beneficial approach, as folate targeted anticancer conjugates are selective towards cancer cells, thereby sparing non-cancerous cells. In this review, we have discussed folate receptor, folic acid as a cancer targeting moiety, different folate targeted anticancer drug conjugates, and different folate conjugated nanodelivery systems. This summarized information may turn out to be valuable for researchers to design novel folate targeted anticancer drug delivery systems having the potential to reduce the drawbacks associated with conventional cancer therapeutics.
- 1 September 2022
- Published by Bentham Science Publishers Ltd. in Current Cancer Therapy Reviews
Recent updates on folate targeted drug delivery systems in cancer: A minireview
Targeted drug delivery systems that selectively deliver anticancer drugs to tumour cells have always been a field of interest to reduce side effects associated with chemotherapy in cancer patients. Cancer cells require nutrients for their multiplication; folic acid is one such nutrient. Expression of folate receptors is negligible in normal cells, whereas they are overexpressed in a variety of cancer cells. A number of studies have shown that selective targeting of folate receptors in cancer is a beneficial approach, as folate targeted anticancer conjugates are selective towards cancer cells, thereby sparing non-cancerous cells. In this review, we have discussed folate receptor, folic acid as a cancer targeting moiety, different folate targeted anticancer drug conjugates, and different folate conjugated nanodelivery systems. This summarized information may turn out to be valuable for researchers to design novel folate targeted anticancer drug delivery systems having the potential to reduce the drawbacks associated with conventional cancer therapeutics.
- 1 September 2022
- Published by Bentham Science Publishers Ltd. in Current Cancer Therapy Reviews
Recent updates on folate targeted drug delivery systems in cancer: A minireview
Targeted drug delivery systems that selectively deliver anticancer drugs to tumour cells have always been a field of interest to reduce side effects associated with chemotherapy in cancer patients. Cancer cells require nutrients for their multiplication; folic acid is one such nutrient. Expression of folate receptors is negligible in normal cells, whereas they are overexpressed in a variety of cancer cells. A number of studies have shown that selective targeting of folate receptors in cancer is a beneficial approach, as folate targeted anticancer conjugates are selective towards cancer cells, thereby sparing non-cancerous cells. In this review, we have discussed folate receptor, folic acid as a cancer targeting moiety, different folate targeted anticancer drug conjugates, and different folate conjugated nanodelivery systems. This summarized information may turn out to be valuable for researchers to design novel folate targeted anticancer drug delivery systems having the potential to reduce the drawbacks associated with conventional cancer therapeutics.
- 1 May 2022
- Published by Bentham Science Publishers Ltd. in Current Cancer Therapy Reviews
- Vol. 18 (2) , 80-86
A Mini-review on Nanodelivery Systems as Therapeutics in Cancer
This review article gives a brief account of advances in the treatment of cancer via nanodelivery systems. We have discussed benefits of different nanocarriers that have the potential to deal with the problem of non-selectivity of conventional anticancer drugs. Targeted drug delivery not only spares healthy cells from harmful effects of anticancer drugs but also reduces the amount of drug to be administered; various drug delivery systems have been fabricated using appropriate nanocarriers. In fact, some carrier systems are biodegradable and degrade in the body into nontoxic moieties, thereby adding safety characteristics to the formulation. Selectivity towards cancer cells makes nanodelivery system a choice for the treatment of cancer as compared to conventional drug delivery. This review discusses various targeting strategies, different nanodelivery systems, characteristics required to be an ideal drug delivery system, advantages of these systems, and future prospects of such systems.
- 1 May 2022
- Published by Bentham Science Publishers Ltd. in Current Cancer Therapy Reviews
- Vol. 18 (2) , 80-86
A Mini-review on Nanodelivery Systems as Therapeutics in Cancer
This review article gives a brief account of advances in the treatment of cancer via nanodelivery systems. We have discussed benefits of different nanocarriers that have the potential to deal with the problem of non-selectivity of conventional anticancer drugs. Targeted drug delivery not only spares healthy cells from harmful effects of anticancer drugs but also reduces the amount of drug to be administered; various drug delivery systems have been fabricated using appropriate nanocarriers. In fact, some carrier systems are biodegradable and degrade in the body into nontoxic moieties, thereby adding safety characteristics to the formulation. Selectivity towards cancer cells makes nanodelivery system a choice for the treatment of cancer as compared to conventional drug delivery. This review discusses various targeting strategies, different nanodelivery systems, characteristics required to be an ideal drug delivery system, advantages of these systems, and future prospects of such systems.
- 10 April 2020
- Published by Bentham Science Publishers Ltd. in Mini-Reviews in Medicinal Chemistry
- Vol. 20 (4) , 260-268
Recent Updates on Antifungal Peptides
The current trend of increment in the frequency of antifungal resistance has brought research into an era where new antifungal compounds with novel mechanisms of action are required. Natural antimicrobial peptides, which are ubiquitous components of innate immunity, represent their candidature for novel antifungal peptides. Various antifungal peptides have been isolated from different species ranging from small marine organisms to insects and from various other living species. Based on these peptides, various mimetics of antifungal peptides have also been synthesized using non-natural amino acids. Utilization of these antifungal peptides is somehow limited due to their toxic and unstable nature. This review discusses recent updates and future directions of antifungal peptides, for taking them to the shelf from the bench.
- 10 April 2020
- Published by Bentham Science Publishers Ltd. in Mini-Reviews in Medicinal Chemistry
- Vol. 20 (4) , 260-268
Recent Updates on Antifungal Peptides
The current trend of increment in the frequency of antifungal resistance has brought research into an era where new antifungal compounds with novel mechanisms of action are required. Natural antimicrobial peptides, which are ubiquitous components of innate immunity, represent their candidature for novel antifungal peptides. Various antifungal peptides have been isolated from different species ranging from small marine organisms to insects and from various other living species. Based on these peptides, various mimetics of antifungal peptides have also been synthesized using non-natural amino acids. Utilization of these antifungal peptides is somehow limited due to their toxic and unstable nature. This review discusses recent updates and future directions of antifungal peptides, for taking them to the shelf from the bench.
- 26 December 2019
- Published by Taylor & Francis in Drug Development and Industrial Pharmacy
- Vol. 46 (1) , 70-79
Formulation and optimization for DPP-4 inhibitor nanomicelles using response surface methodology
Objective: DPP-4 (Dipeptidyl peptidase-4) inhibitors are the oral antidiabetics that inhibits the enzyme DPP-4. The main aim of study was to formulate, statistically optimize and characterize the polymeric nanomicellar (PNM) formulation of DPP-4 inhibitor (sitagliptin) using natural polymer and a non-ionic surfactant. Method: Response surface methodology (RSM) an experimental design was applied for optimization of nanomicelles using full central composite design. Drug and polymer concentration are independent variables (each at two factor three level) whereas drug loading (% DL) (R1), entrapment efficiency (% EE) (R2) and % drug release (R3) were identified as dependent variables. The polymeric nanomicelles were prepared by direct dissolution method and characterized for surface morphology, particle size, polydispersity index, zeta potential, entrapment efficiency, drug loading and % drug release. Results: The optimized formulation of sitagliptin loaded polymeric nanomicelles (PNM 10) was found to be clear, homogenous nanomiceller solution with round spherical structures with a low poly dispersity index of 0.564. PNM 10 has particle size of 368.2 nm. PNM 10 showed drug loading of 38.67 ± 0.23%, entrapment efficiency of 79.67 ± 0.54% and % drug release (R3) of 82.34 ± 0.78%. Conclusion: Design- Expert (DOE) version 11.0.5.0 software (Stat-Ease Inc, USA) was used for statistically optimization of formulations. PNM 10 was considered best optimized formulation and highly stable for prolonged use and found to be safe for application. Thus this can be a futuristic approach for developing nanomicelles, which can minimize the possible side effects of drug.
- 26 December 2019
- Published by Taylor & Francis in Drug Development and Industrial Pharmacy
- Vol. 46 (1) , 70-79
Formulation and optimization for DPP-4 inhibitor nanomicelles using response surface methodology
Objective: DPP-4 (Dipeptidyl peptidase-4) inhibitors are the oral antidiabetics that inhibits the enzyme DPP-4. The main aim of study was to formulate, statistically optimize and characterize the polymeric nanomicellar (PNM) formulation of DPP-4 inhibitor (sitagliptin) using natural polymer and a non-ionic surfactant. Method: Response surface methodology (RSM) an experimental design was applied for optimization of nanomicelles using full central composite design. Drug and polymer concentration are independent variables (each at two factor three level) whereas drug loading (% DL) (R1), entrapment efficiency (% EE) (R2) and % drug release (R3) were identified as dependent variables. The polymeric nanomicelles were prepared by direct dissolution method and characterized for surface morphology, particle size, polydispersity index, zeta potential, entrapment efficiency, drug loading and % drug release. Results: The optimized formulation of sitagliptin loaded polymeric nanomicelles (PNM 10) was found to be clear, homogenous nanomiceller solution with round spherical structures with a low poly dispersity index of 0.564. PNM 10 has particle size of 368.2 nm. PNM 10 showed drug loading of 38.67 ± 0.23%, entrapment efficiency of 79.67 ± 0.54% and % drug release (R3) of 82.34 ± 0.78%. Conclusion: Design- Expert (DOE) version 11.0.5.0 software (Stat-Ease Inc, USA) was used for statistically optimization of formulations. PNM 10 was considered best optimized formulation and highly stable for prolonged use and found to be safe for application. Thus this can be a futuristic approach for developing nanomicelles, which can minimize the possible side effects of drug.